Vetoquinol SA (8JM.F)
Frankfurt · EUR · Healthcare · Drug Manufacturers - Specialty & Generic
€80.10 (+4.30%) as of
Key statistics
- Market cap
- 931.13M
- P/E (TTM)
- 14.72
- EPS (TTM)
- 5.44
- Dividend yield
- 1.21%
- 52-week range
- 65.30 – 89.70
- Beta
- 0.83
- Revenue (TTM)
- 527.34M
- Profit margin
- 11.91%
- Volume
- 200.00
About Vetoquinol SA
Vetoquinol SA, a veterinary pharmaceutical company, engages in designing, developing, and selling of veterinary drugs and non-medicinal products for cattle, pigs, dogs, and cats in Europe, the Americas, and the Asia Pacific region. It offers products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; antibiotics; reproduction; behavior management; internal medicine; and cardio-nephrology. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA operates as a subsidiary of Soparfin SCA.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Lure, France
- Employees
- 2,526
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.